Max Rivera: Clara, my neighbor's kid was just diagnosed with something I'd never heard of — some genetic metabolic thing — and the doctor told them there's no approved treatment. And I'm sitting there thinking, we approve drugs constantly, how is that possible?
Clara Bennett: That gap is exactly what we're here to talk about. And the number that makes it strange is this: more than half of all recent FDA approvals are orphan drugs — drugs for conditions affecting fewer than 200,000 Americans. More than half.
Max Rivera: Wait, more than half — like, the FDA is now majority orphan-drug approvals?
Clara Bennett: Yes. And yet there are roughly 10,000 distinct rare diseases, and the vast majority still have no approved treatment. So the volume is there — it's just not distributed across the problem.
Max Rivera: That's — I mean, that's what broke my brain about my neighbor's kid. Because 1 in 10 Americans has a rare disease, that's 25 to 30 million people, and somehow the system is producing record-level approvals and still leaving most of those diseases completely uncovered.
Clara Bennett: The Orphan Drug Act of 1983 was built to solve a real market failure — the economics of developing drugs for tiny populations just didn't work before it existed. And it solved that. But 'solving market failure' and 'treating most rare diseases' turn out not to be the same goal.
Max Rivera: So the act worked — it's just that what it was designed to do and what we assumed it would do are two different things.
Clara Bennett: In practice, yes. The speed-versus-scale tradeoff built into this system is the thing we need to actually name — because once you see it, the approval numbers stop looking like a success story and start looking like a map of where the incentives point.
Max Rivera: Okay but — wait, I want to back up to the 'where the incentives point' part, because I don't think I actually understand what the incentives *are*. Like, what did 1983 change, mechanically?
Clara Bennett: Picture a bakery that can only sell twelve loaves. You wouldn't buy the industrial oven. That's what drug development looked like before the Orphan Drug Act — the math never worked. Too few patients, too much cost, zero upside.
Max Rivera: Right — so nobody even started.
Clara Bennett: Nobody started. So Public Law 97-414 in 1983 didn't just encourage development — it changed the economic structure. Three specific things: seven years of market exclusivity where the FDA cannot approve a competing application for the same drug and disease, tax credits on clinical trial costs, and user fee waivers from the FDA itself. That's the whole incentive stack.
Max Rivera: Hold on — seven years where nobody else can even apply? That's not a patent thing, that's separate?
Clara Bennett: Completely separate. Patent protection and seven-year market exclusivity run on different clocks. You could lose your patent and still have exclusivity, or the reverse. It's a regulatory guarantee — the FDA just won't process a competitor's application during that window.
Max Rivera: Huh. So now I want to ask the obvious dumb question — does getting this designation actually lower the evidence bar to get the drug approved? Because that feels like the assumption.
Clara Bennett: That's the crucial distinction. Orphan Drug Designation unlocks the incentive stack — the exclusivity, the tax credits, the fee waivers — but it does not waive the approval requirements. The FDA still requires proof that the drug works. Now, what *does* compress the timeline is that rare disease sponsors disproportionately qualify for fast track and breakthrough therapy designation, because structurally the unmet need is almost always high. So the development is faster, but not because the bar dropped.
Max Rivera: So the system worked — and then something happened.
Clara Bennett: Worked — yes. And then the incentive structure started selecting. Not for greatest unmet need. For diseases that are easiest to monetize. Identifiable biomarkers, tractable biology, an existing patient registry. That's what gets picked.
Max Rivera: So — wait. Picture the parent of a kid with a genetic metabolic disorder, 800 patients in the U.S., devastating, progressive. Nobody's working on it. And meanwhile a pharma company just secured orphan designation for a subgroup of a disease that already had a treatment.
Clara Bennett: That's not a hypothetical. That's the salami-slicing problem. Companies take a larger disease population, subdivide it — genetically, by severity — until each subgroup falls under 200,000 patients. Each subgroup gets its own orphan designation. Each one unlocks a fresh seven-year exclusivity window.
Max Rivera: That's — I mean, that's legal?
Clara Bennett: DrugPatentWatch documents it as exactly that — legal gamesmanship with no clear regulatory remedy. The FDA's definition is drug-disease-delivery combination. So a narrower disease definition is a different combination.
Max Rivera: So the FDA can't actually push back. It's not — I mean, there's no rule being broken. The rule is being used. And the 800-patient kid's disease never had a subgroup worth subdividing in the first place, so it just... stays invisible.
Clara Bennett: Which is why GAO-25-106774 — the 2025 report — matters. The GAO found the FDA has steps underway to strengthen coordination of rare disease drug development. That's institutional language for: the system requires active management, and right now it isn't getting enough.
Max Rivera: And companies like Alnylam and United Therapeutics — they're not villains here. They file SEC disclosures around orphan drug incentives because that's the rational response to the structure that exists.
Clara Bennett: Rational actors, designed incentives. And the part that makes all of this messier — we haven't even gotten to what happens after approval, when the evidence is built on surrogate endpoints and the price never comes down. It's genuinely hard to defend.
Max Rivera: Wait — so the drug gets approved, patient gets it, and we still don't actually know if it works in the way that matters?
Clara Bennett: That's the accelerated approval pathway. The FDA approves on a surrogate endpoint — tumor shrinkage, a lab value — something measurable that's reasonably likely to predict clinical benefit. Confirmatory trials are required post-market. But 'required' and 'completed on schedule' are not the same thing.
Max Rivera: So patients are on these drugs long-term while the actual outcome data is — what, still being collected?
Clara Bennett: In some cases, yes. ICER has pushed specifically on this — stronger post-market evidence requirements as a literal condition of sustained market access, not just a filing obligation.
Max Rivera: Okay but if the high price was supposed to offset development risk for a tiny market, why doesn't the price move when, say, the same drug gets approved for a second indication? The risk is already recovered at that point, I mean — right?
Clara Bennett: It doesn't move. Orphan drugs launch at persistently high prices and additional indications don't correct that. And during the seven-year exclusivity window there's no generic competition to create any downward pressure at all.
Max Rivera: That's — that's the thing that breaks the market failure logic for me. Because the whole justification was correcting an economic problem. If the price never adjusts even after the risk is demonstrably recouped, then it's not a correction anymore.
Clara Bennett: And that's exactly ICER's critique. The pricing has decoupled from clinical benefit. So you can have an accelerated approval built on a surrogate endpoint — real-world outcomes still unresolved — and a launch price that doesn't scale to what the drug actually demonstrated.
Max Rivera: Both layers at once. Thin evidence and full price.
Clara Bennett: Which is the question the system hasn't answered: at what point does the incentive stop correcting a market failure and start just generating a premium-pricing mechanism? It's genuinely uncomfortable.
Max Rivera: That's the thing I can't — I mean, I keep trying to land somewhere with this and I can't. Because 1 in 10 Americans has a rare disease. That's real scale. But the individual drug serves thousands of patients, not millions. So the framework that was supposed to help all of them is basically — it's routing investment toward whichever rare diseases happen to be easiest to build a business case around. And the 800-patient metabolic disorder just never makes that cut.
Clara Bennett: The Orphan Drug Act of 1983 worked. That's the honest answer. It corrected a real market failure. But it was designed to create any incentive where none existed — not to distribute investment fairly across all 10,000 rare diseases. Whether that design still fits what we're asking it to do now? That I genuinely cannot resolve.
Max Rivera: Yeah. Me neither.
Clara Bennett: Good conversation to sit with, though. Genuinely.
